Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

hippocampus48 940 posts  |  Last Activity: Sep 29, 2014 9:49 AM Member since: Jul 25, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • hippocampus48 by hippocampus48 Sep 29, 2014 9:49 AM Flag

    no indicaction that CERS plasma will get reviewed by the BPAC in December. Not a good sign! Dont let all this ebola plasma treatment thing fog your thinking. It does seem viable but remember that there are already a number of PI methods used for treating plasma used in the EU, they have been used longer and are much cheaper than CERS method and if you are not concerned with the clotting factors there is no reason to go with Intercept. There is no indication that the UK is even thinking of reviewing Intercept plasma or platelets regardless of what some may imply here. The future is very uncertain here and the risk is very large, except for short positions established above $4.

  • Reply to

    Cerus = Alibaba like growth potential?

    by mymandon Sep 19, 2014 12:41 PM
    hippocampus48 hippocampus48 Sep 19, 2014 2:18 PM Flag

    Wow! You have totally lost touch with reality. Comparing CERS to BABA. There is no contract in the UK and there wont be for a very long time. How long do you think "expanding sales in EU" will take? How does expanding sales take CERS to guiding revenues down for 2014? $60M for 2015? I dont hear CERS saying this, only you . You have to be delusional. Guys fall in love with stocks but you are way past that bordering on a stalkers obsession! You are transfusing millions of Intercept red cells, when the company is still hoping for plasma approval, an approval process that is taking more than a year!

    Sentiment: Strong Sell

  • Institutional share ownership dropped 2.4%/over 1 million shares last quarter. Mutual fund share ownership dropped 24.7%/ 2.5 million shares. Its now been over a year since the FDA has had the plasma submission and no approval yet. End of year selling will be brutal!

    Sentiment: Strong Sell

  • hippocampus48 hippocampus48 Sep 17, 2014 8:43 AM Flag

    Pay no attention to anything a33geezer posts here. He has been waiting for CERS to become profitable for 10 years and he has been watching it daily. Waiting, waiting, waiting.........for that day that will never come, the day CERS makes its first profit.

  • hippocampus48 hippocampus48 Sep 12, 2014 10:25 AM Flag

    Because there really wasnt any good news. Fluff about a distributorship in Italy that has nothing to do with increased sales and another about the early use of intercept platelets which would only be used if a catastrophic outbreak of dengue/chikunyunga occurred in southern states and has nothing to do the FDA approval process of intercept plasma/platelets.

    Sentiment: Sell

  • hippocampus48 by hippocampus48 Sep 11, 2014 12:04 PM Flag

    "Cerus Corporation (CERS) announced today that it has entered into an agreement with Biomedica Foscama Group S.p.A (BFG) to distribute the INTERCEPT Blood System for plasma and platelets in Italy, with a goal of expanding the adoption of pathogen inactivation to improve blood safety. More than 200,000 platelet and over 400,000 plasma units are produced annually by Italian blood centers for transfusion"

    Ask CERS how many kits they sell in Italy right now this year, last year, the year before. LMAO I bet CERS goal is to sell at least a zillion worldwide.

    Sentiment: Strong Sell

  • hippocampus48 by hippocampus48 Sep 11, 2014 11:56 AM Flag

    Must be getting desperate to release this garbage about Italy. Yup they sell a lot of product in Italy. LOL Think about it folks, if the FDA was close to a review on intercept platelets do you think the company would file an early use? Nope they know the FDA is having some problems with their submission and that platelet review is somewhere in 2016. These long delays between submission and review does not spell success!

  • Revenues are way down, expenses way up. Submitting paper must be very expensive? Would have been cheaper to fund another P3 to get platelets approved.

    Sentiment: Sell

  • hippocampus48 hippocampus48 Sep 10, 2014 2:04 PM Flag

    Yup, a little hype, a few hedge funds and you got your typical pump and dump. $3.80 by the end of September and down from there. Yes people are greedy and stupid. Fluff news all about what could be, not will most likely happen................... that intercept platelets get used here in USA before a final decision is made by the FDA in 2016 is a very slim prospect.

    Sentiment: Sell

  • Reply to

    Baird Conference--Sep

    by drbro01 Aug 27, 2014 5:26 PM
    hippocampus48 hippocampus48 Sep 3, 2014 10:44 AM Flag

    Sounds like the conference was gangbusters! LOL. Off like a rocket! LOL Must have been super upbeat! Maybe they talked about early use all over the USA . LOL. No need for FDA approval! Maybe they heard a birdie telling them UK was ready for adopting Intercept. LOL Maybe CERS told them they were going to make 110% on every kit sold. It gets funnier by the minute.

    Sentiment: Strong Sell

  • Reply to

    Baird Conference--Sep

    by drbro01 Aug 27, 2014 5:26 PM
    hippocampus48 hippocampus48 Sep 3, 2014 10:07 AM Flag

    Do you know what short interest is? Sure BB owns a ton of shares. Who do you think has been increasing the amount of shares short? Who is hedging in the option market? They arent in this with two feet anymore, in fact if CERS goes bust with an outright rejection I bet they breakeven. Sure they wont make a fortune if CERS succeeds but I dont think they are 100% sure on CERS anymore.

    Sentiment: Strong Sell

  • hippocampus48 hippocampus48 Sep 3, 2014 9:53 AM Flag

    And how does CERS make a cent on this? More clinical trials for the next 3 years? Too bad the company cant even make a profit in the EU? Maybe Africa is greener pasture? LOL Notice how mymandon no longer talks about plasma/platelet approval in USA.

    Sentiment: Strong Sell

  • Reply to

    Baird Conference--Sep

    by drbro01 Aug 27, 2014 5:26 PM
    hippocampus48 hippocampus48 Aug 31, 2014 4:10 PM Flag

    The corporate update? lol Like this guys know anything, they cant even get a plasma filing done right using hemovigilant data. lol But we are working on a red cell product by the way. lol. No we dont have kit designed for that yet but we are sure to submit sometime in 2017. lol

  • hippocampus48 hippocampus48 Aug 26, 2014 2:35 PM Flag

    The company should defintely pursue this indication since it seems they wont be getting plasma/platelets approved by the FDA anytime in 2014. At least it would divert shareholder attention away from the cost associated with getting all the submission data together for the FDA to review in 2013-2014.

    Sentiment: Strong Sell

  • Holy mackeral! This is not going to end well for those long not fully hedged! End of August and not a hint of when plasma will be addressed? Do you have a sinking feeling? Id say something is very very wrong here.

  • Reply to

    Cerus 2nd half catalysts

    by mymandon Aug 19, 2014 11:26 AM
    hippocampus48 hippocampus48 Aug 25, 2014 7:55 AM Flag

    I guess we no longer talk about plasma or platelet review and approval any more as 2nd half catalysts LOL

    Sentiment: Strong Sell

  • Reply to

    Cerus 2nd half catalysts

    by mymandon Aug 19, 2014 11:26 AM
    hippocampus48 hippocampus48 Aug 20, 2014 8:48 AM Flag

    (The current RBC kit may indeed be modified as you say for commercialization in trade dress, but that doesn't require new phase III studies since the active ingredients will be the same.)

    That is not true. CERS will have to define the commercial red cell kit before it can begin P3. The FDA does not allow you to submit P3 from one kit and then use another kit for commercial use. That "same ingredients"
    statement was very amusing.

    Why would the FDA change for Chickunyunga and not for West Nile or Chagas? They wont change for the chikun. LOL

    The dynamics of the uptake for rbcs no one can explain, not even you. The cost of switching to rbc PI would be enormous and will not be implemented quickly if it ever comes to pass. Because of the enormous added cost the political debate about risk/benefit will drag on for years. Even in France most of the platelets are not PI. In Germany the same thing, only a small percentage after 10 years? But yet you see quick and universal acceptance by major nations! Listen to the conference call? And believe all the rosey scenario garbage the management feeds you? They are supposed to be cheerleaders, their job is to sell the company. Read the scientific debates on PI versus screening/testing for more realistic views.

    I will tell your right now the FDA is biased against PI versus testing, and that is going to make me a bunch of money.

    Sentiment: Strong Sell

  • Reply to

    Cerus 2nd half catalysts

    by mymandon Aug 19, 2014 11:26 AM
    hippocampus48 hippocampus48 Aug 19, 2014 1:44 PM Flag

    Early use does not mean FDA approval, it does not lead to any significant revenue. Phase 2 RBC data?phase 3 EU RBC data in 2014? Do you live in Denver? Smoking the weed day in and day out can cause hallucinations. Please reference and prove me wrong. They dont even have a finalized kit yet for RBC. Uptake swift? Like in EU where Intercept platelets have been used for 10 years? The UK is broke, they will not adopt PI unless the USA and Canada adopt,so that means never.

  • Reply to

    This is just the start! This is not good!

    by hippocampus48 Aug 18, 2014 9:57 AM
    hippocampus48 hippocampus48 Aug 19, 2014 10:19 AM Flag

    I think you need to read the filing.

  • hippocampus48 hippocampus48 Aug 19, 2014 10:01 AM Flag

    Form 4 CERUS CORP For: Aug 14 Filed by: COZADD BRUCE C

    A positive sign! At least someone thinks CERS si worth $2. LOL. The Baker Bros is old news not present news, big players often load more before they dump to throw investors off the scent.

CRIS
1.42-0.15(-9.55%)Feb 5 4:00 PMEST